Key result
High-quality, higher potency vaccines (≥ 6 PD50) reduce FMD virus subclinical circulation and the risk of carriers, supporting the feasibility of vaccinate-to-live policies.
Population
Animals in countries with OIE status facing FMD outbreaks
Comparison
Higher potency, high-purity vaccines formulated… vs Vaccinate-to-die policies / standard vaccines
Design
Review
Authors
Loading...
May support aligning FMD waiting periods for vaccinate-to-live policies; leaves open prospective field validation before practice change.
High-potency vaccines and DIVA testing can reduce FMDV circulation and carrier risk, supporting the feasibility of aligning waiting periods for vaccinate-to-live and vaccinate-to-die policies.
Barnett et al. (2013) conducted a review in Foot-and-Mouth Disease. Vaccinate-to-live policy using higher potency vaccines vs. Vaccinate-to-die policy was evaluated on FMD virus subclinical circulation and risk of carriers. High-quality, higher potency vaccines (≥ 6 PD50) reduce FMD virus subclinical circulation and the risk of carriers, supporting the feasibility of vaccinate-to-live policies.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: